Key result
PCSK9 inhibitors reduce major cardiovascular events ~17% versus placebo in patients with diabetes.
Why the study?
PCSK9 inhibitors substantially lower LDL cholesterol, but their effect on hard cardiovascular endpoints, mortality, and safety in patients with diabetes had not been comprehensively quantified, especially after the VESALIUS-CV trial.
Do PCSK9 inhibitors reduce major adverse cardiovascular events and mortality without increasing safety events in patients with diabetes mellitus?
Meta-Analysis (n=20,317)
Do PCSK9 inhibitors reduce major adverse cardiovascular events and mortality without increasing safety events in patients with diabetes mellitus?
PCSK9 inhibitors significantly reduce major adverse cardiovascular events by 17% in patients with diabetes without increasing serious adverse events, hypertension, or mortality.
Answers are grounded in this paper and cite their sources.
Supports PCSK9 inhibitor use for MACE prevention in diabetes; confirms benefit across 8 RCTs without mortality or safety signals.
Introduction: Diabetes presents a high risk of atherosclerotic cardiovascular events. PCSK9 inhibitors lower LDL cholesterol substantially, but their effect on hard cardiovascular endpoints, mortality, and safety in patients with diabetes has not been comprehensively quantified especially after VESALIUS-CV trial . We performed a systematic review and meta-analysis of randomized controlled trials to evaluate the cardiovascular efficacy and safety of PCSK9 inhibitors in diabetes. Methods: A systematic search conducted across PubMed, Embase, Scopus and Web of Science identified articles on PCSK9 inhibitors in patients with diabetes mellitus. Random-effects model pooled Risk Ratios (RR) with 95% CI for dichotomous outcomes using R Software. Sensitivity analysis was conducted using common effects model and leave one out analysis approach. Results: Eight randomized controlled trials ( n = 20317) comprising patients with diabetes mellitus were included. PCSK9 inhibitors significantly reduced major adverse cardiovascular events (MACE) compared with placebo (6 trials; RR 0.83, 95% CI 0.77-0.89; P<0.0001), with no heterogeneity (I 2 =0.0%; prediction interval 0.75-0.91). This benefit was consistent across agents and was robust to sensitivity analysis. All-cause mortality was not reduced significantly (8 trials; RR 0.92, 95% CI 0.70-1.21; I 2 =13.9%). However, leave-one-out analysis showed the pooled estimate became significant on the omission of FOURIER (RR 0.80, 95% CI 0.69-0.93, P = 0.0042, I 2 =0%) and attenuated when VESALIUS was omitted (RR 1.08, 95% CI 0.9-1.29, P = 0.3968, I 2 =0%). Cardiovascular death did not differ between the two groups (2 trials; RR 0.92, 95% CI 0.71-1.20; I 2 =53.5%). For safety, PCSK9 inhibitors did not increase serious adverse events (8 trials; RR 0.98, 95% CI 0.92-1.05; I 2 =0.0%) or incident hypertension (6 trials; RR 0.97, 95% CI 0.57-1.67; I 2 =41.0%). Overall, PCSK9 inhibitors reduced MACE without increasing mortality, serious adverse events, or hypertension in diabetes. Conclusion: PCSK9 inhibitors are associated with significant reduction in major adverse cardiovascular events without significant effect on all-cause or cardiovascular mortality. They were not associated with an increased risk of serious adverse events or hypertension. These findings support PCSK9 inhibition as an effective and well-tolerated strategy for cardiovascular risk reduction in diabetes.
No takes yet. Share an insight, caveat, or question.
Qasim et al. (2026) conducted a meta-analysis in Diabetes mellitus (n=20,317). PCSK9 inhibitors vs. Placebo was evaluated on Major adverse cardiovascular events (MACE) (RR 0.83, 95% CI 0.77-0.89, p=<0.0001). PCSK9 inhibitors reduced major adverse cardiovascular events compared with placebo in patients with diabetes.
Synapse has enriched 10 related papers. Consider them for comparative context: